All In Biotech

Drug Trial Radar · NCT05809830

Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas

Phase I/II Randomized Trial of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas

Last checked: Nov 19, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

152

Planned (sponsor's estimate)

Start

May 29, 2023

Primary completion

Jun 20, 2025

Study completion May 8, 2026

Sponsor

Lead sponsor
Grupo Espanol de Investigacion en SarcomasAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I dose-finding stage for the LB-100 plus doxorubicin combination is planned for an initial set of 9-18 patients (21-day cycles). After that, in the Phase II part, patients will be randomized (ratio 1:1) to either the experimental arm (LB-100 plus doxorubicin combination) or the control arm (doxorubicin alone) to, comparatively, evaluate the efficacy of the LB-100 plus doxorubicin combination vs. doxorubicin alone

Conditions

  • Advanced Soft-tissue Sarcoma

Interventions

  • LB-100 plus DoxorrubicinDrug

    In Phase one the intervention will be LB-100 plus Doxorrubicin. The experimental arm in Phase II will also be LB-100 plus Doxorrubicin

  • DoxorubicinDrug

    The control arm in Phase II will be Doxorrubicin alone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximun Tolerated Dose (MTD) (Phase I)Time frame: After six months
  2. Progression-free survival (PFS) (Phase II)Time frame: After two years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Catalonia, Spain

  • Hospital Clínico San Carlos

    Madrid, Madrid, Spain

  • Hospital Fundación Jiménez Díaz

    Madrid, Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Madrid, Spain

  • Hospital Clínico Universitario Virgen de la Arrixaca

    Murcia, Murcia, Spain

  • Hospital Clínico Universitario de Valencia

    Valencia, Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.